glp-1 receptor agonist function Frontiers Frontiers | Exploring the multifaceted

Minamiyama Y, Takemura S, Ichikawa H

The better the foundation, the better CJC 1295 can do its job

In a retrospective analysis of 182 patients with MDS with various subtypes, the multivariate analysis revealed a significant benefit in OS for patients receiving ICT with 140.9 months vs 36.3 months (p=0.0008) in case of refractory anemia (RA or, according to the present WHO classification: MDS-RS), 133.4 months vs 73.3 months (p=0.02) in case of refractory anemia with ring sideroblasts (RARS/RARS-t, corresponding to MDS-RS according to the present WHO classification) and no difference for refractory cytopenia with multilineage dysplasia (RCMD/RCMD-RS, corresponding to MDS-MLD according to the present WHO classification) (146)

Flj tillverkarens anvisningar och utg frn din kliniska bedmning nr du planerar behandlingen

FASEB J 34(5):65216538